Envista Stock Price, News & Analysis (NYSE:NVST)

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Envista in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NVST shares.
View NVST analyst ratings or view top-rated stocks.

7 brokerages have issued 12 month price targets for Envista's shares. Their NVST share price targets range from $25.00 to $45.00. On average, they anticipate the company's stock price to reach $34.63 in the next twelve months. This suggests a possible upside of 44.9% from the stock's current price.
View analysts price targets for NVST or view top-rated stocks among Wall Street analysts.

Envista's stock was trading at $33.67 at the beginning of the year. Since then, NVST stock has decreased by 29.0% and is now trading at $23.89.
View the best growth stocks for 2023 here.

Envista saw a increase in short interest in October. As of October 31st, there was short interest totaling 7,630,000 shares, an increase of 30.7% from the October 15th total of 5,840,000 shares. Based on an average daily volume of 2,180,000 shares, the days-to-cover ratio is presently 3.5 days.
View Envista's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 14th 2024.
View our NVST earnings forecast.

Envista Holdings Co. (NYSE:NVST) posted its earnings results on Wednesday, November, 1st. The company reported $0.43 EPS for the quarter, missing analysts' consensus estimates of $0.46 by $0.03. The firm earned $631.30 million during the quarter, compared to analysts' expectations of $647.94 million. Envista had a trailing twelve-month return on equity of 7.29% and a net margin of 7.39%. Envista's revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.47 EPS.

ETFs with the largest weight of Envista (NYSE:NVST) stock in their portfolio include Thrivent Small-Mid Cap ESG ETF (TSME), First Trust Health Care AlphaDEX Fund (FXH), Schwab Ariel ESG ETF (SAEF), SPDR S&P Health Care Equipment ETF (XHE), SPDR S&P 400 Mid Cap Value ETF (MDYV), Vanguard S&P Mid-Cap 400 Value Index Fund (IVOV), iShares U.S. Medical Devices ETF (IHI) and iShares S&P Mid-Cap 400 Value ETF (IJJ).

9 employees have rated Envista Chief Executive Officer Amir Aghdaei on Glassdoor.com. Amir Aghdaei has an approval rating of 21% among the company's employees. This puts Amir Aghdaei in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

(NVST) raised $603 million in an initial public offering on Wednesday, September 18th 2019. The company issued 26,800,000 shares at $21.00-$24.00 per share. J.P. Morgan, Goldman Sachs and Morgan Stanley acted as the underwriters for the IPO and Baird, Evercore ISI, Jefferies, BofA Merrill Lynch, Credit Suisse, Stifel and William Blair were co-managers.

Envista's stock is owned by a number of institutional and retail investors. Top institutional investors include Lazard Asset Management LLC (4.41%), Massachusetts Financial Services Co. MA (4.04%), Gates Capital Management Inc. (3.30%), Ariel Investments LLC (3.11%), Charles Schwab Investment Management Inc. (1.13%) and Montrusco Bolton Investments Inc. (1.11%). Insiders that own company stock include Amir Aghdaei, Curt W Bludworth, Curt W Bludworth, Eric Conley, Howard H Yu, Jeffrey Kappler, Mark E Nance, Mark E Nance, Mischa Reis and Stephen Keller.
View institutional ownership trends.

Shares of NVST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.